Holen Sie sich die Stockscreener-App
1.25
3.85%
-0.05
Vorhandelsmarkt:
1.25
Schlusskurs vom Vortag:
$1.30
Offen:
$1.28
24-Stunden-Volumen:
206.49K
Relative Volume:
0.06
Marktkapitalisierung:
$29.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-178.01M
KGV:
-0.1501
EPS:
-8.326
Netto-Cashflow:
$-7.87M
1W Leistung:
+5.93%
1M Leistung:
+6.84%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.20
$1.2899
1-Wochen-Bereich:
$1.1101
$1.33
52-Wochen-Spanne:
$0.81
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Firmenname
Lunai Bioworks Inc
Sektor
Branche
Telefon
45 39179840
Adresse
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Vergleichen Sie LNAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
1.25 | 30.46M | 0 | -178.01M | -7.87M | -8.326 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lunai Bioworks Inc Aktie (LNAI) Neueste Nachrichten
Lunai Bioworks (LNAI) Stock Analysis Report | Financials & Insights - Benzinga
Lunai Bioworks enters sales agreement with Dawson James SecuritiesSEC filing - marketscreener.com
Lunai Bioworks Enters Sales Agreement with Dawson James - TipRanks
Does Lunai Bioworks Inc (LNAI) offer a good opportunity for investors? - Setenews
Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license - MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Lunai Bioworks - The Pharma Letter
Lunai Bioworks lands first licensing deal for off-the-shelf cancer immunotherapy - The Pharma Letter
There is no way Lunai Bioworks Inc (LNAI) can keep these numbers up - Setenews
Lunai Bioworks Inc (2Q50.MU) latest stock news and headlines - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Shares Decline Amidst New Licensing Agreement - Stocks Telegraph
Lunai Bioworks Secures $3.1M in Private Placement - TipRanks
Lunai Bioworks sells 3,133,333 shares in private financing deal - Stock Titan
LNAI Stock: Surging or Slipping? - StocksToTrade
Lunai Bioworks (LNAI) Stock: Plummets 14.2% Despite Breakthrough in Cancer Immunotherapy - parameter.io
Lunai Bioworks Shares Rise After Company Secures Licensing Intent for Dendritic Cell Therapy - marketscreener.com
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy By Investing.com - Investing.com South Africa
LNAI's Groundbreaking Immune Cell Therapy Advances with Key Lice - GuruFocus
Lunai Bioworks Secures First Licensing LOI Following Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - MarketScreener
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - Yahoo Finance
Lunai Bioworks rises on early licensing interest in DCCT therapy | Tap to know more | Inshorts - Inshorts
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Routine Trading Amid Price Decline - Stocks Telegraph
Lunai Bioworks Inc (2Q50.MU) options chain - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -13.9% in Normal Trading: Price Declines Amid Routine Trading - Stocks Telegraph
What is the current Price Target and Forecast for Lunai Bioworks Inc. (LNAI) - Zacks Investment Research
Lunai Bioworks Inc. announced that it expects to receive $3.133333 million in funding - marketscreener.com
Lunai Bioworks Inc Com (LNAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lunai Bioworks Inc (2Q50.MU) analyst ratings, estimates and forecasts - Yahoo Finance Australia
Lunai Bioworks Inc (2Q50.MU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Are Smart Investors Making the Right Decision? Lunai Bioworks Inc (LNAI) - Setenews
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Greenville Online
Lunai Bioworks Inc. (LNAI) stock price, news, quote and history - Yahoo Finance Australia
Lunai Bioworks: Fiscal Q1 Earnings Snapshot - New Haven Register
Lunai Bioworks Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025 - MarketScreener
[10-Q] Lunai Bioworks Inc. Quarterly Earnings Report | RENB SEC FilingForm 10-Q - Stock Titan
A better buy-in window may exist right now for Lunai Bioworks Inc (LNAI) - Setenews
A Mandatory Rebranding: Lunai Bioworks Emerges from Enochian’s Ashes - Ad-hoc-news.de
Lunai Bioworks Inc. (2Q50.F) Company Profile & Facts - Yahoo! Finance Canada
Lunai Bioworks Inc. (LNAI) Stock Major Holders - Yahoo! Finance Canada
Top Biotech Stocks To Follow NowNovember 5th - MarketBeat
Lunai Bioworks Inc. (LNAI) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Lunai Bioworks Inc. (LNAI) latest press releases and corporate news - Yahoo Finance UK
Top Biotech Stocks To Follow Now – November 5th - Defense World
Lunai Bioworks Inc (2Q50.MU) Latest Press Releases & Corporate News - Yahoo! Finance Canada
[8-K] Lunai Bioworks Inc. Reports Material Event | RENB SEC FilingForm 8-K - Stock Titan
Lunai Bioworks Inc. (LNAI) stock historical prices and data - Yahoo Finance UK
Lunai Bioworks Inc. (LNAI) interactive stock chart - Yahoo Finance UK
Lunai Bioworks Inc. (LNAI) Stock Price, News, Quote & History - Yahoo! Finance Canada
This trade activity should not be overlooked: Lunai Bioworks Inc (LNAI) - Setenews
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthro - ANP Persportaal
Finanzdaten der Lunai Bioworks Inc-Aktie (LNAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):